Laser Sharp Understanding of Risk Management and Mitigation Mechanisms Biotechnology has helped to improve the lives of millions if not billions of people from all across the globe.
May 29, Their business plan was unusual and hard — to develop pheromones, a kind of chemicals that can change the behaviour of insects. Gorantla wanted to use pheromones to disrupt the mating of insects and, thus, provide the farmer with a clean option for pest control.
ATGC was set up in At present, only one company in the world sells pheromones for pest control — Japanese firm Shin Etsu. Large seed companies such as Monsanto do not develop pheromones themselves, but fund small companies doing this.
In its seven years of existence, this Hyderabad-based company claims to have developed 58 different pheromones, some of which are under field trials in India at the moment.
ATGC has raised roughly Rs 14 crore through government grants. The main patents were developed bywhen the company was formally set up. Then there were trials using a series of Indian and international grants, raising about Rs crore each year.
The product, if it works commercially, would be nothing short of revolutionary. You could call them the third generation of biotech startups in India. They are founded by experienced scientists and develop difficult technologyoften using novel science.
They have global ambitions and are looking at making a big impact on the Indian industry and society. They are also a diverse bunch. Entrepreneurs are setting up companies for regenerative medicine, new methods of drug delivery, novel biocompatible materials, molecular diagnostics, nutrition, sustainable energy, and agriculture.
Some engineering startups are trying to solve healthcare and agriculture problems, thereby stretching the definition of biotechnology. Others develop products vital for biotech research.
These startups are joining the older product, services and manufacturing companies to create a strong foundation for a future biotechnology industry. Over 1, were set up in ABLE estimates, based on new registrations, that biotech startups were formed last year. The biotechnology sector has created more than 3, entrepreneurs, one-third of whom are women.
But the new-generation product startups are led by experienced entrepreneurs, and thus considered highly attractive by investors.
One such man is Jogin Desai. The year-old doctor-manager worked as the global chief executive of Cenduit, a US-based clinical trials management company, before moving to India to set up Eyestem.
Desai was intrigued by the possibilities of regenerative medicine, especially for curing degenerative retinal diseases. Eyestem chose two retinal diseases for attack — age-related macular degeneration and retinitis pigmentosa. Age-related macular degeneration is the leading cause of blindness after the age of 60 and there are million people affected by the disease around the world.
Retinitis pigmentosa is a rare disease that begins by the age of Scientists believe transplanting stem cells to the retina can help patients grow healthy retinal cells and thus cure the blindness. But stem cell therapy is tough and fraught with risks. Desai brings the global regulatory experience that can help scientists look ahead.
His strategy is to be based in Bengaluru but leverage specialised skills from around the world. So, Eyestem has a set of advisors and collaborators in the country and in some of the best labs in the world. The company has started growing retinal cells in its lab through a unified protocol that can used by technicians and hopes to begin clinical trials by Fertile ground When the first generation of biotechnology startups began to be formed 20 years ago, India did not have experienced people like Desai.
The initial set of companies were set up either by scientists who had no business experience, or by entrepreneurs with business backgrounds.
They were mostly services companies, as it was impossible to get funding for product development over long periods. India was not a big market for biotechnology, and so venture capitalists were not interested. So, industry observers are not surprised that most of the initial set shut down after several years of struggle.
Those who survived either did pure services, such as Genotypic Technologies, or continued to tweak their business model and evolve continuously, like Strand Life Sciences. The current generation of entrepreneurs has good early funding through government programmes.Starting a biotech company requires trainings, experience, creativity, reasonable startup capital, license and detailed business plan.
The truth is that you can’t just wake up and launch your own biotech company; you must follow established protocols. Cayenne Consulting has a long history in the San Francisco Bay area.
Cayennen’s CEO, Akira Hirai, was a co-founder of funded Internet startups in Cupertino and San Francisco in and (he also interned at the Stanford Linear Accelerator Center in the mids)..
Several of Cayenne Consulting’s first business plan consulting clients were in . Starting a biotech company requires trainings, experience, creativity, reasonable startup capital, license and detailed business plan. The truth is that you can’t just wake up and launch your own biotech company; you must follow establish protocols.
See Biotechnology startup jobs at startups.
Apply privately. Get salary, equity and funding info upfront. Biotechnology Tech & Startup Jobs Internship · San Francisco Bay Area · Business Operations · Logistics · Communication Skills · Compliance. The San Francisco Bay Area has long been regarded as an epicenter of technology and a leading biotech cluster, but now, the tech and biotech sectors are, literally, beginning to collide.
For starters, more collaboration between tech and biotech is taking hold. Gail Maderis, President & CEO, BayBio. Known as the birthplace of the biotech industry, the San Francisco Bay Area is home to many firsts: the first biotechnology company, the first biotech public offering, the first biotech drug .